NASDAQ · SRPT
Healthcare · Biotechnology
$18.54
Up+$0.45 (+2.43%)
Updated Nov 4, 2026, 9:27 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SRPT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SRPT closed at $18.54 after 21 trading sessions, up 7.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $18.44 | $18.805 | $18.25 | $18.54 | 1.4M |
| Nov 2, 2026 | $18.65 | $18.90 | $18.10 | $18.32 | 1.16M |
| Oct 30, 2026 | $19.04 | $19.50 | $18.41 | $18.62 | 1.32M |
| Oct 29, 2026 | $19.195 | $19.6819 | $18.96 | $19.23 | 1.19M |
| Oct 28, 2026 | $18.77 | $19.33 | $18.50 | $19.32 | 1.36M |
| Oct 27, 2026 | $18.05 | $18.89 | $17.69 | $18.89 | 2.23M |
| Oct 26, 2026 | $17.77 | $18.14 | $17.655 | $17.98 | 1.36M |
| Oct 23, 2026 | $17.94 | $18.12 | $17.155 | $17.73 | 1.29M |
| Oct 22, 2026 | $18.40 | $18.9369 | $18.115 | $18.18 | 1.24M |
| Oct 21, 2026 | $19.05 | $19.30 | $18.49 | $18.56 | 2.03M |
| Oct 20, 2026 | $17.74 | $19.695 | $17.655 | $19.17 | 3.33M |
| Oct 19, 2026 | $17.25 | $17.83 | $17.12 | $17.73 | 2.33M |
| Oct 16, 2026 | $17.82 | $17.84 | $16.85 | $17.10 | 9.86M |
| Oct 15, 2026 | $16.96 | $17.955 | $16.61 | $17.79 | 4.04M |
| Oct 14, 2026 | $16.53 | $16.91 | $16.3675 | $16.83 | 2.74M |
| Oct 13, 2026 | $17.12 | $17.23 | $16.41 | $16.51 | 3.69M |
| Oct 12, 2026 | $17.88 | $18.14 | $17.30 | $17.44 | 3.28M |
| Oct 9, 2026 | $18.245 | $18.525 | $17.68 | $17.85 | 3.02M |
| Oct 8, 2026 | $17.275 | $18.28 | $17.20 | $18.21 | 3.52M |
| Oct 7, 2026 | $17.28 | $17.665 | $16.98 | $17.50 | 2.87M |
| Oct 6, 2026 | $17.60 | $17.65 | $17.04 | $17.31 | 2.69M |
The latest Smart Investors Daily articles mentioning SRPT.
Company
Market Activity
Research & News
SRPT research
Company profile and research snapshot.
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 5, 2026 | HC Wainwright & Co. | Sell | — |
| Sep 30, 2026 | JP Morgan | Neutral | — |
| Sep 28, 2026 | Needham | Underperform | — |
| Jul 9, 2026 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Is RARE a good stock to buy? We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on r/ValueInvesting by u/Tallwhitedude123. Since the thesis was published on August 30th, RARE shares have pulled back as a key pipeline setback shifted investor focus to whether its approved drugs can drive enough growth to offset the lost opportunity. In […]
Yahoo · Oct 30, 2026
Why Sarepta Therapeutics Stock Is Back in Focus Sarepta Therapeutics (SRPT) returns to the spotlight as investors look ahead to its November 5 earnings release, with expectations for higher quarterly earnings alongside lower revenue for the September 2026 period. Sarepta Therapeutics has seen its 90-day share price return climb 29.41%, including an 8.46% move over the past week. However, the year-to-date share price is still down 9.76% and the 5-year total shareholder return has fallen...
Yahoo · Oct 29, 2026
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo · Oct 28, 2026
For questions about this article or underlying research, email [email protected].
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SRPT.
